Bio-Techne (TECH) Stock Forecast, Price Target & Predictions
TECH Stock Forecast
Bio-Techne stock forecast is as follows: an average price target of $99.21 (represents a 31.79% upside from TECH’s last price of $75.28) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
TECH Price Target
The average price target for Bio-Techne (TECH) is $99.21 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $125.00 to $83.00. This represents a potential 31.79% upside from TECH's last price of $75.28.
TECH Analyst Ratings
According to 6 Wall Street analysts, Bio-Techne's rating consensus is 'Buy'. The analyst rating breakdown for TECH stock is 0 'Strong Buy' (0.00%), 3 'Buy' (50.00%), 2 'Hold' (33.33%), 1 'Sell' (16.67%), and 0 'Strong Sell' (0.00%).
Bio-Techne Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 16, 2024 | Sung Ji Nam | Scotiabank | $83.00 | $74.19 | 11.87% | 10.26% |
| Dec 14, 2022 | - | Deutsche Bank | $100.00 | $86.98 | 14.97% | 32.84% |
| Dec 12, 2022 | - | Citigroup | $100.00 | $80.73 | 23.87% | 32.84% |
| Dec 07, 2022 | - | RBC Capital | $89.00 | $80.67 | 10.33% | 18.23% |
| Dec 05, 2022 | - | Stephens | $105.00 | $82.44 | 27.37% | 39.48% |
| May 05, 2022 | Paul Knight | KeyBanc | $125.00 | $98.96 | 26.31% | 66.05% |
| Apr 25, 2022 | - | Wells Fargo | $92.50 | $100.75 | -8.19% | 22.87% |
| May 06, 2021 | Patrick B Donnelly | Citigroup | $106.25 | $102.45 | 3.71% | 41.14% |
The latest Bio-Techne stock forecast, released on Aug 16, 2024 by Sung Ji Nam from Scotiabank, set a price target of $83.00, which represents a 11.87% increase from the stock price at the time of the forecast ($74.19), and a 10.26% increase from TECH last price ($75.28).
Bio-Techne Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $83.00 | $83.00 |
| Last Closing Price | $75.28 | $75.28 | $75.28 |
| Upside/Downside | -100.00% | 10.26% | 10.26% |
In the current month, the average price target of Bio-Techne stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bio-Techne's last price of $75.28. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 16, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Aug 13, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| May 22, 2024 | Deutsche Bank | Buy | Buy | Hold |
| May 22, 2024 | Citigroup | Buy | Neutral | Downgrade |
| May 02, 2024 | Scotiabank | Outperform | Outperform | Hold |
| Feb 02, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Aug 28, 2023 | William Blair | - | Outperform | Initialise |
| Dec 14, 2022 | Deutsche Bank | - | Buy | Initialise |
| Dec 12, 2022 | Citigroup | - | Buy | Upgrade |
| Dec 07, 2022 | RBC Capital | - | Sector Perform | Initialise |
Bio-Techne's last stock rating was published by Scotiabank on Aug 16, 2024. The company gave TECH a "Sector Outperform" rating, the same as its previous rate.
Bio-Techne Financial Forecast
Bio-Techne Revenue Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $272.60M | $276.94M | $301.32M | $294.15M | $271.58M | $269.65M | - | $290.38M | $269.28M | $257.72M | $259.03M | $243.55M | $224.25M | $204.20M | $175.83M | $194.68M |
| Avg Forecast | $404.33M | $383.23M | $339.97M | $332.40M | $361.53M | $348.68M | $311.58M | $304.58M | $329.47M | $319.82M | $284.91M | $280.84M | $306.49M | $292.15M | $277.55M | $287.66M | $307.22M | $296.61M | $288.80M | $281.83M | $286.71M | $279.27M | $266.44M | $252.78M | $244.65M | $228.22M | $206.50M | $185.03M | $163.91M | $185.93M |
| High Forecast | $414.48M | $392.86M | $348.51M | $340.75M | $370.61M | $357.44M | $319.41M | $312.23M | $337.75M | $327.85M | $292.06M | $285.67M | $314.19M | $299.49M | $285.67M | $292.69M | $314.94M | $304.06M | $296.05M | $288.91M | $286.71M | $284.23M | $271.17M | $257.27M | $249.00M | $232.27M | $210.17M | $188.32M | $166.82M | $189.23M |
| Low Forecast | $396.21M | $375.54M | $333.15M | $325.73M | $354.27M | $341.69M | $305.33M | $298.47M | $322.86M | $313.40M | $279.19M | $277.93M | $300.34M | $286.29M | $271.57M | $282.89M | $301.05M | $290.66M | $283.00M | $276.17M | $286.71M | $275.56M | $262.90M | $249.42M | $241.40M | $225.19M | $203.76M | $182.58M | $161.73M | $183.46M |
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 7 | 10 | 10 | 10 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 0.96% | 0.98% | 0.99% | 0.94% | 0.96% | - | 1.04% | 1.01% | 1.02% | 1.06% | 1.07% | 1.09% | 1.10% | 1.07% | 1.05% |
Bio-Techne's average Quarter revenue forecast for Mar 24 based on 4 analysts is $292.15M, with a low forecast of $286.29M, and a high forecast of $299.49M. TECH's average Quarter revenue forecast represents a 7.17% increase compared to the company's last Quarter revenue of $272.60M (Dec 23).
Bio-Techne EBITDA Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 7 | 10 | 10 | 10 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $38.00M | $84.40M | $121.45M | $107.18M | $94.59M | $82.96M | - | $115.81M | $122.30M | $96.16M | $35.39M | $69.50M | $80.97M | $64.84M | $87.13M | $72.42M |
| Avg Forecast | $121.27M | $114.95M | $101.97M | $99.70M | $108.44M | $104.58M | $93.45M | $91.35M | $98.82M | $95.93M | $85.45M | $84.23M | $91.93M | $100.87M | $83.25M | $86.28M | $92.15M | $91.70M | $86.62M | $104.40M | $79.73M | $83.37M | $116.15M | $94.91M | $30.58M | $58.74M | $66.19M | $44.62M | $58.09M | $57.30M |
| High Forecast | $124.32M | $117.83M | $104.53M | $102.20M | $111.16M | $107.21M | $95.80M | $93.65M | $101.30M | $98.34M | $87.60M | $85.68M | $94.24M | $121.05M | $85.68M | $87.79M | $94.46M | $110.04M | $88.80M | $125.28M | $79.73M | $100.04M | $139.38M | $113.89M | $36.69M | $70.48M | $79.43M | $53.54M | $69.71M | $68.76M |
| Low Forecast | $118.84M | $112.64M | $99.92M | $97.70M | $106.26M | $102.48M | $91.58M | $89.52M | $96.84M | $94.00M | $83.74M | $83.36M | $90.08M | $80.70M | $81.45M | $84.85M | $90.30M | $73.36M | $84.88M | $83.52M | $79.73M | $66.69M | $92.92M | $75.93M | $24.46M | $46.99M | $52.95M | $35.69M | $46.47M | $45.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.46% | 0.98% | 1.32% | 1.17% | 1.09% | 0.79% | - | 1.39% | 1.05% | 1.01% | 1.16% | 1.18% | 1.22% | 1.45% | 1.50% | 1.26% |
4 analysts predict TECH's average Quarter EBITDA for Mar 24 to be $100.87M, with a high of $121.05M and a low of $80.70M. This is 165.43% upper than Bio-Techne's previous annual EBITDA (Dec 23) of $38.00M.
Bio-Techne Net Income Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 7 | 10 | 10 | 10 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $27.46M | $50.99M | $75.48M | $70.22M | $50.01M | $89.56M | - | $60.74M | $72.06M | $69.61M | $14.96M | $45.78M | $46.27M | $33.40M | $58.84M | $36.43M |
| Avg Forecast | $114.92M | $104.03M | $80.77M | $76.97M | $101.18M | $94.61M | $73.04M | $70.81M | $89.65M | $83.65M | $62.14M | $61.56M | $79.51M | $64.67M | $66.22M | $69.83M | $87.80M | $58.80M | $78.42M | $75.58M | $83.31M | $53.45M | $76.14M | $68.71M | $12.92M | $38.69M | $37.83M | $22.98M | $39.23M | $28.83M |
| High Forecast | $118.67M | $107.42M | $83.41M | $79.48M | $104.49M | $97.70M | $75.42M | $73.12M | $92.57M | $86.38M | $64.17M | $64.81M | $82.10M | $77.61M | $70.95M | $76.18M | $90.67M | $70.55M | $80.98M | $90.70M | $83.31M | $64.14M | $91.37M | $82.45M | $15.51M | $46.43M | $45.40M | $27.57M | $47.08M | $34.59M |
| Low Forecast | $111.92M | $101.31M | $78.66M | $74.96M | $98.54M | $92.14M | $71.13M | $68.96M | $87.31M | $81.47M | $60.52M | $58.32M | $77.43M | $51.74M | $61.49M | $65.07M | $85.51M | $47.04M | $76.37M | $60.47M | $83.31M | $42.76M | $60.91M | $54.97M | $10.34M | $30.95M | $30.26M | $18.38M | $31.38M | $23.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.41% | 0.73% | 0.86% | 1.19% | 0.64% | 1.18% | - | 1.14% | 0.95% | 1.01% | 1.16% | 1.18% | 1.22% | 1.45% | 1.50% | 1.26% |
Bio-Techne's average Quarter net income forecast for Mar 24 is $64.67M, with a range of $51.74M to $77.61M. TECH's average Quarter net income forecast represents a 135.48% increase compared to the company's last Quarter net income of $27.46M (Dec 23).
Bio-Techne SG&A Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 7 | 10 | 10 | 10 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $115.67M | $105.33M | $86.75M | $99.24M | $93.01M | $99.38M | - | $89.27M | $100.69M | $86.17M | $51.61M | $82.60M | $83.12M | $72.60M | $65.80M | $66.32M |
| Avg Forecast | $140.47M | $133.14M | $118.11M | $115.48M | $125.60M | $121.14M | $108.25M | $105.82M | $114.46M | $111.11M | $98.98M | $97.57M | $106.48M | $95.05M | $96.42M | $99.94M | $106.73M | $86.41M | $100.33M | $93.56M | $99.89M | $78.56M | $95.63M | $85.06M | $44.59M | $69.81M | $67.95M | $49.95M | $43.86M | $52.48M |
| High Forecast | $144.00M | $136.49M | $121.08M | $118.38M | $128.76M | $124.18M | $110.97M | $108.47M | $117.34M | $113.90M | $101.47M | $99.25M | $109.15M | $114.06M | $99.25M | $101.69M | $109.41M | $103.69M | $102.85M | $112.27M | $99.89M | $94.27M | $114.76M | $102.07M | $53.51M | $83.77M | $81.54M | $59.94M | $52.64M | $62.97M |
| Low Forecast | $137.65M | $130.47M | $115.74M | $113.16M | $123.08M | $118.71M | $106.08M | $103.69M | $112.17M | $108.88M | $96.99M | $96.56M | $104.34M | $76.04M | $94.35M | $98.28M | $104.59M | $69.13M | $98.32M | $74.85M | $99.89M | $62.85M | $76.50M | $68.04M | $35.67M | $55.85M | $54.36M | $39.96M | $35.09M | $41.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.20% | 1.05% | 0.81% | 1.15% | 0.93% | 1.06% | - | 1.14% | 1.05% | 1.01% | 1.16% | 1.18% | 1.22% | 1.45% | 1.50% | 1.26% |
Bio-Techne's average Quarter SG&A projection for Mar 24 is $95.05M, based on 4 Wall Street analysts, with a range of $76.04M to $114.06M. The forecast indicates a -17.82% fall compared to TECH last annual SG&A of $115.67M (Dec 23).
Bio-Techne EPS Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 7 | 10 | 10 | 10 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.17 | $0.32 | $0.48 | $0.45 | $0.32 | $0.57 | - | $0.39 | $0.46 | $0.42 | $0.09 | $0.28 | $0.29 | $0.21 | $0.37 | $0.23 |
| Avg Forecast | $0.72 | $0.65 | $0.50 | $0.48 | $0.63 | $0.59 | $0.45 | $0.44 | $0.56 | $0.52 | $0.39 | $0.38 | $0.49 | $0.45 | $0.41 | $0.43 | $0.55 | $0.53 | $0.49 | $0.46 | $0.52 | $0.50 | $0.45 | $0.43 | $0.43 | $0.39 | $0.34 | $0.28 | $0.19 | $0.29 |
| High Forecast | $0.74 | $0.67 | $0.52 | $0.49 | $0.65 | $0.61 | $0.47 | $0.46 | $0.58 | $0.54 | $0.40 | $0.40 | $0.51 | $0.47 | $0.44 | $0.47 | $0.56 | $0.55 | $0.50 | $0.47 | $0.52 | $0.51 | $0.46 | $0.44 | $0.44 | $0.40 | $0.35 | $0.28 | $0.19 | $0.29 |
| Low Forecast | $0.70 | $0.63 | $0.49 | $0.47 | $0.61 | $0.57 | $0.44 | $0.43 | $0.54 | $0.51 | $0.38 | $0.36 | $0.48 | $0.44 | $0.38 | $0.41 | $0.53 | $0.51 | $0.48 | $0.45 | $0.52 | $0.49 | $0.44 | $0.42 | $0.42 | $0.38 | $0.34 | $0.27 | $0.18 | $0.28 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.41% | 0.74% | 0.88% | 0.85% | 0.66% | 1.25% | - | 0.78% | 1.03% | 0.98% | 0.21% | 0.73% | 0.84% | 0.76% | 1.97% | 0.80% |
According to 4 Wall Street analysts, Bio-Techne's projected average Quarter EPS for Mar 24 is $0.45, with a low estimate of $0.44 and a high estimate of $0.47. This represents a 166.34% increase compared to TECH previous annual EPS of $0.17 (Dec 23).
Bio-Techne Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.32 | $33.86 | 1359.48% | Buy |
| REPL | Replimune Group | $11.03 | $24.20 | 119.40% | Buy |
| APLS | Apellis Pharmaceuticals | $35.53 | $75.38 | 112.16% | Buy |
| LQDA | Liquidia | $9.78 | $17.17 | 75.56% | Buy |
| AKRO | Akero Therapeutics | $26.64 | $46.00 | 72.67% | Buy |
| LEGN | Legend Biotech | $51.17 | $78.78 | 53.96% | Buy |
| BMRN | BioMarin Pharmaceutical | $70.55 | $107.74 | 52.71% | Buy |
| TVTX | Travere Therapeutics | $14.40 | $21.60 | 50.00% | Buy |
| TECH | Bio-Techne | $75.28 | $99.21 | 31.79% | Buy |
| ASND | Ascendis Pharma | $146.59 | $189.07 | 28.98% | Buy |
| BGNE | BeiGene | $197.51 | $247.75 | 25.44% | Buy |
| BPMC | Blueprint Medicines | $86.51 | $101.50 | 17.33% | Buy |
| PCVX | Vaxcyte | $116.75 | $124.14 | 6.33% | Buy |
| NUVL | Nuvalent | $104.75 | $109.40 | 4.44% | Buy |
| EXEL | Exelixis | $27.60 | $28.30 | 2.54% | Buy |
| HALO | Halozyme Therapeutics | $61.93 | $56.86 | -8.19% | Buy |
| ALNY | Alnylam Pharmaceuticals | $274.46 | $250.16 | -8.85% | Buy |
| UTHR | United Therapeutics | $345.02 | $312.50 | -9.43% | Buy |
TECH Forecast FAQ
Is Bio-Techne a good buy?
Yes, according to 6 Wall Street analysts, Bio-Techne (TECH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 50.00% of TECH's total ratings.
What is TECH's price target?
Bio-Techne (TECH) average price target is $99.21 with a range of $83 to $125, implying a 31.79% from its last price of $75.28. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bio-Techne stock go up soon?
According to Wall Street analysts' prediction for TECH stock, the company can go up by 31.79% (from the last price of $75.28 to the average price target of $99.21), up by 66.05% based on the highest stock price target, and up by 10.26% based on the lowest stock price target.
Can Bio-Techne stock reach $110?
TECH's highest twelve months analyst stock price target of $125 supports the claim that Bio-Techne can reach $110 in the near future.
What are Bio-Techne's analysts' financial forecasts?
Bio-Techne's analysts financial forecasts for the fiscal year (Jun 2026) are as follows: average revenue is $1.33B (high $1.36B, low $1.3B), average EBITDA is $397.83M (high $407.82M, low $389.84M), average net income is $339.64M (high $350.73M, low $330.78M), average SG&A $460.8M (high $472.38M, low $451.55M), and average EPS is $2.11 (high $2.18, low $2.06). TECH's analysts financial forecasts for the fiscal year (Jun 2027) are as follows: average revenue is $1.46B (high $1.5B, low $1.43B), average EBITDA is $437.89M (high $448.89M, low $429.1M), average net income is $376.68M (high $388.98M, low $366.85M), average SG&A $507.2M (high $519.95M, low $497.03M), and average EPS is $2.34 (high $2.42, low $2.28).
Did the TECH's actual financial results beat the analysts' financial forecasts?
Based on Bio-Techne's last annual report (Jun 2023), the company's revenue was $1.14B, which missed the average analysts forecast of $1.46B by -22.21%. Apple's EBITDA was $406.18M, missing the average prediction of $454.61M by -10.65%. The company's net income was $285.26M, missing the average estimation of $383.9M by -25.69%. Apple's SG&A was $378.38M, missing the average forecast of $486.93M by -22.29%. Lastly, the company's EPS was $1.81, missing the average prediction of $2.54 by -28.72%. In terms of the last quarterly report (Dec 2023), Bio-Techne's revenue was $272.6M, missing the average analysts' forecast of $277.55M by -1.78%. The company's EBITDA was $38M, missing the average prediction of $83.25M by -54.35%. Bio-Techne's net income was $27.46M, missing the average estimation of $66.22M by -58.52%. The company's SG&A was $115.67M, beating the average forecast of $96.42M by 19.96%. Lastly, the company's EPS was $0.17, missing the average prediction of $0.412 by -58.76%